Seelos Therapeutics, Inc.
SEELDelisted Apr 4, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001017491
Seelos Therapeutics, Inc. was delisted on Apr 4, 2025; its insiders filed their last Form 4 on Mar 1, 2024; 23 institutions reported holding it in 13F filings for Q2 2024, worth $129.4K in total; no superinvestor held it.
Q2 2023 vs. Q1 2023
How the institutions holding Seelos Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 80 | 1 | 83 | +4 |
| Shares | 21.9M | 40.5K | 22.8M | +1.02M (+4.7%) |
| Value | $15.1M | $28.0K | $27.1M | +$12.0M (+79.6%) |
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held Seelos Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Woodline Partners LP | 573,986 | $685.9K | 0.01% |
| Susquehanna International Group, LLP | 53,048 | $63.4K | 0.00% |
| Gsa Capital Partners LLP | 48,018 | $57.0K | 0.01% |
| State of Wyoming | 33,417 | $39.9K | 0.01% |
| Two Sigma Securities, LLC | 31,321 | $37.4K | 0.00% |
| Cubist Systematic Strategies, LLC | 24,132 | $28.8K | 0.00% |
| North Star Investment Management Corp. | 21,000 | $25.1K | 0.00% |
| Lazard Asset Management LLC | 16,184 | $19.0K | 0.00% |
| Jump Financial, LLC | 11,900 | $14.2K | 0.00% |
| Curtis Advisory Group, LLC | 11,200 | $13.4K | 0.00% |
Sold out (6)
Institutions that held Seelos Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Belpointe Asset Management LLC | 50,000 | $34.6K |
| Jane Street Group, LLC | 18,283 | $12.6K |
| Sawtooth Solutions, LLC | 10,000 | $6.91K |
| Ameritas Advisory Services, LLC | 466 | $326 |
| TCI Wealth Advisors, Inc. | 200 | $139 |
| US Bancorp | 100 | $69 |
Not filed for Q2 2023 yet (1)
Institutions that held Seelos Therapeutics, Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Asset Management Corp | 40,500 | $28.0K |